Improving Patient Outcomes through Personalized AI-Enabled Medicine

Dhiti Omics Technologies from India Integrates SOPHiA DDM™ Platform

Philogen and Sun Pharma: EMA Validates Nidlegy Marketing Authorization Application for Skin Cancer Treatment

Orchid Pharma Appoints Key Leaders for Newly Established AMR Division

Beacon Therapeutics Secures $170 Million in Series B Funding to Propel Advancements in Ophthalmic Gene Therapies

Indica Labs Broadens HALO Digital Pathology Solutions Availability in Asia Pacific, Featuring CE-IVDR Marked HALO AP® Platform

Sudha Murty's Rajya Sabha Debut: Advocating for Cervical Cancer Prevention

Aurigene Partners with Edity for Cell Therapy Discovery Services to Accelerate Clinical Development

FDA Greenlights Eli Lilly's Anti-Amyloid Alzheimer's Drug Kisunla

TauRx Applies for UK Marketing Authorization for HMTM as Alzheimer’s Disease Treatment

Nutrition Redefined: Harnessing Genetics for Personalized Wellness

FDA Clears FoundationOne Liquid CDx for Identifying BRCA-Mutated mCRPC Patients Eligible for Janssen's Akeega

ACT Genomics and LSI Medience Forge Strategic Partnership to Advance in the Japanese Market

Key Components of Precision Prevention for Breast Cancer

Advancing Cervical Cancer Screening: The Scope of Digital Cytology

Home
/
update
/
details

Aurigene Partners with Edity for Cell Therapy Discovery Services to Accelerate Clinical Development

NextEdge Admin

03 Jul 2024

2 min 22 sec

gene therapy,Cell therapy,autoimmune disorders,regenerative medicine

Aurigene Pharmaceutical Services, an India-based contract research, development, and manufacturing organization (CRO/CDMO), announced on July 1, 2024, a partnership with Israel-based Edity Therapeutics. This collaboration aims to advance cell therapy discovery services, leveraging Edity’s innovative immune cell delivery platform. Edity focuses on precise intracellular protein delivery to target cells with high specificity, crucial for therapies in oncology, gene therapy, autoimmune disorders, and regenerative medicine.

The agreement follows an initial strategic collaboration started between Edity and Aurigene’s parent company, Dr. Reddy’s Laboratories, in January 2024. Aurigene, known for its expertise in biologics and advanced therapies such as antibodies, antibody-drug conjugates (ADCs), and viral vectors, will now extend its capabilities to support Edity’s novel technologies. This includes enhancing the efficacy of CAR-T cell therapeutics through Edity’s cellular reprogramming approach.

Roger Lias, Aurigene’s global commercial head of biologics, highlighted their comprehensive service offering—from discovery through large-scale CGMP manufacture—as pivotal in delivering high-quality and economically viable solutions. This aligns with Aurigene’s strategic focus on cost-effective manufacturing of both small molecules and biologics.

Edity’s CEO, Michal Golan Mashiach, expressed enthusiasm about collaborating with Aurigene’s team, expecting their technological breadth and experience to accelerate Edity’s pipeline development. The partnership aims to address challenges in solid tumor therapy, including antigen heterogeneity and the immunosuppressive tumor microenvironment.

The alliance underscores Aurigene’s role as a preferred partner in global biologics and advanced therapies, dedicated to advancing innovative treatments and ultimately improving patient outcomes across severe diseases.